Natalizumab
- Generic Name
- Natalizumab
- Brand Names
- Tysabri, Tyruko
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 189261-10-7
- Unique Ingredient Identifier
- 3JB47N2Q2P
- Background
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for mu...
- Indication
Natalizumab is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
...
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Severe Crohn's Disease, Moderate Crohn’s Disease
- Associated Therapies
- -
Natalizumab De-escalation With Interferon Beta-1b
- Conditions
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Claudio Gobbi
- Target Recruit Count
- 19
- Registration Number
- NCT01144052
- Locations
- 🇨🇭
Neurocenter of Southern Switzerland, Ospedale Civico Lugano, Lugano, Ticino, Switzerland
Natalizumab Treatment of Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 24
- Registration Number
- NCT01077466
- Locations
- 🇩🇰
Danish Multiple Sclerosis Center, Section 2082, Rigshospitalet, Copenhagen, Denmark
Treatment Interruption of Natalizumab
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 175
- Registration Number
- NCT01071083
- Locations
- 🇪🇸
Research Site, Valencia, Spain
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 35895
- Registration Number
- NCT01070836
- Locations
- 🇵🇷
Research Site, Ponce, Puerto Rico
Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
- Conditions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2011-03-30
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 300
- Registration Number
- NCT00942214
- Locations
- 🇫🇷
service de neurologie, hôpital Purpan, Toulouse, France
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00831649
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- Conditions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00801125
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00744679
- Locations
- 🇺🇸
Research Site, Latham, New York, United States
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
- Conditions
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 87
- Registration Number
- NCT00707512
- Locations
- 🇵🇷
Research site, San Juan, Puerto Rico
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 76
- Registration Number
- NCT00559702
- Locations
- 🇺🇸
Research Site, Vienna, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.